Release date: January 1, 2008
Available for credit through: January 1, 2009
Estimated time to complete activity: 1.5 hrs.
Program Description:
Myocardial ischemia secondary to acute restrictions in coronary artery blood flow leads to acute coronary syndromes (ACS). Dual antiplatelet therapy with aspirin and clopidogrel is the standard of care for patients with ACS. However, resistance to these agents is associated with adverse clinical events, and is of great concern to clinicians. This educational program will review clinical data pertinent to the current state of antiplatelet therapy for the management of patients with ACS. This will include a discussion of the prevalence of aspirin and clopidogrel resistance. Our esteemed faculty will also highlight the current and emerging treatment options for the management of antiplatelet-refractory patients with ACS. Upon completion of this activity, physicians will be equipped with the necessary knowledge to diagnose and treat their patients with ACS who are resistant to dual antiplatelet therapy.
This archived educational activity, a CME-sponsored web cast, was originally presented as a live activity on December 8, 2007.
Accreditation:
The Cardiovascular Research Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
The Cardiovascular Research Foundation designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Educational Objectives:
• Compare and contrast the classes of antiplatelet therapy, agents in each class, and their role in the treatment of patients with ACS
• Analyze the prevalence of aspirin and clopidogrel resistance, current knowledge of the etiology, and laboratory tests to determine resistance
• Interpret the results of clinical trials of antiplatelet agents in development
Target Audience:
This activity is designed to meet the educational needs of Clinical Cardiologists, Interventional Cardiologists and Cardiovascular Surgeons.
Activity Evaluation:
Evaluation by questionnaire will address content, presentation, possible bias, and future educational needs.
Disclosure of Financial Interests:
It is the policy of the Cardiovascular Research Foundation to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational programs. Commercial support from industry does not influence educational content, faculty selection, and/or faculty presentations, and, therefore, does not compromise the scientific integrity of the educational activity. Discussion of off-label product usage is made at the sole discretion of the faculty and is not endorsed by the Cardiovascular Research Foundation or the program directors for this activity. Faculty participating in continuing medical education activities sponsored by the Cardiovascular Research Foundation are required to disclose to the program audience any real or apparent conflict of interest related to the content of their presentation(s). Faculty not complying with this policy are not permitted to participate in this activity.
Staff Disclosure Declarations:
The employees of ArcMesa Educators have no financial relationships to disclose.
Faculty Disclosure Declarations: Deepak L. Bhat Research Grant: BEACON co-PI – Heartscape, CHAMPION co-PI – The Medicines Company, CHARISMA PI – Bristol-Myers Squibb, Sanofi-Aventis, CRESCENDO PI – Sanofi-Aventis, LANCELOT co-PI – Eisai, REACH co-PI – Bristol-Myers Squibb, Sanofi-Aventis, STAMPEDE co-PI – Ethicon Speakers Bureau: Bristol-Myers Squibb, Sanofi-Aventis, The Medicines Company Honoraria: AstraZeneca, Bristol-Myers Squibb, Centocor, Eisai, Eli Lilly, GlaxoSmithKline, Millennium, Paringenix, PDL, Sanofi-Aventis, Schering Plough, The Medicines Company, TNS Healthcare
Consultant/Advisory Board: Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Cardax, Centocor, Cogentus, Daiichi- Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, McNeil, Medtronic, Millennium, Molecular Insights, Otsuka, Paringenix, PDL, Philips, Portola, Sanofi-Aventis, Schering Plough, Scios, The Medicines Company, TNS Healthcare, Vertex Institution/Employer: Abraxis, Alexion Pharma, AstraZeneca, Atherogenics, Aventis, Biosense Webster, Biosite, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardionet, Centocor, Converge Medical Inc., Cordis, Dr. Reddy’s, Edwards Lifesciences, Esperion, GE Medical, Genentech, Gilford, GlaxoSmithKline, Guidant, J&J, Kensey-Nash, Lilly, Medtronic, Merck, Mytogen, Novartis, Novo Nordisk, Orphan Therapeutics, P&G Pharma, Pfizer, Roche, Sankyo, Sanofi-Aventis, Schering-Plough, Scios, St. Jude Medical, Takeda, TMC, VasoGenix, Viacor Expert Witness: Provided expert testimony regarding clopidogrel
Cindy L. Grines Research Grants – Aventis, Cardium Therapeutics, Portola, Takeda Pharmaceuticals, Cardiovascular Research Foundation Consultant/Advisory Board – CV Therapeutics, Inc., Cordis, Possis
Peter B. Berger – Honorarium Recipient: Bristol-Myers Squibb, Sanofi-Aventis, the Medicines Company, AstraZeneca, Medtronic, Sheering Plough, and Lilly/Daiichi Sankyo Consultant: PlaCor, Lilly/Daiichi Sankyo, Molecular Insight Pharmaceuticals and CV Therapeutics Shareholder: Lumen, Inc.
Repurposing Statement:
If you previously completed and received credit for the live activity on December 8, 2007, you will not receive credit for this activity. Learning benefits may be accrued by revisiting learning materials presented in Internet-based, self-directed activities; however, participants cannot claim duplicate credit for the activity.
How to Receive Credit:
To obtain CME credit for this activity, participants must review all CME information, participate in the CME activity in its entirety (view each presentation in its entirety), complete the Post-Test, Activity/Faculty Evaluation Form, and the Request for Credit Form. After completing the activity, click on the Post Test link to get to the Post-Test and Activity Evaluation.
System Requirements Windows 98, 2000, XP, 2003 and Vista
• Internet Explorer 6/7
• Firefox 2
• Mozilla 1.7 or higher
• Netscape 8.1 or higher
• JavaScript and cookies need to be enabled
• Recommend ActiveX be enabled for Internet Explorer
• Vista supports Internet Explorer 7 and Firefox 2 browsers only Mac OS X 10.3, 10.4
• Safari 1.3 (Mac OS 10.3)
• Safari 2.0 (Mac OS 10.4)
• Firefox 2
• JavaScript and cookies need to be enabled
• Requires Java Runtime Environment (JRE) 5.0 or higher
Printer settings may vary. Please use landscape layout option.
Program Chair -
Deepak L. Bhatt, MD, FACC, FSCAI, FESC, FACP, FCCP, FAHA Associate Director, Cardiovascular Coordinating Center
Staff, Cardiac, Peripheral, and Carotid Intervention
Associate Professor of Medicine, Department of Cardiovascular Medicine, Cleveland Clinic
Cindy L. Grines, MD, FACC Director, Cardiac Cath Laboratories, Director, Interventional Cardiology Fellowship Program, William Beaumont Hospital
Peter B. Berger, MD Associate Chief Research Officer
Director, Geisinger Center for Clinical Studies
